Olema Boosts Its Partnering Position With SERD Combo Data

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.